Brief Summary

The QUAD-HF registry is an observational study that would enroll patients in the United Kingdom, who have been newly diagnosed with heart failure and a left ventricular ejection fraction \<50%. We plan to assess clinical outcomes in these patients, such as hospitalization and death, in relation to their diagnosis, implementation of guidelines and type of treatments these patients have received.

Trial Health

On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment

4,000

participants targeted

Target at P75+ for all trials

Timeline

67mo left

Started Oct 2025

Longer than P75 for all trials

Geographic Reach

1 country

2 active sites

Status

recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

6.1 years study duration

Study Progress10%

Oct 2025Nov 2031

First Submitted

Initial submission to the registry

September 12, 2025

Completed

3 days until next milestone

First Posted

Study publicly available on registry

September 15, 2025

Completed

21 days until next milestone

Study Start

First participant enrolled

October 6, 2025

Completed

5.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2030

Expected

1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2031

Last Updated

December 16, 2025

Status Verified

September 1, 2025

Enrollment Period

5.1 years

First QC Date

September 12, 2025

Last Update Submit

December 8, 2025

Conditions

Heart Failure

Keywords

Observational CohortHeart FailureLongitudinal

Outcome Measures

Primary Outcomes (1)

Cardiovascular Mortality or Hospitalization for Heart Failure
Death due to cardiac causes or hospitalization due to worsening heart failure symptoms
From enrolment to 12 months after diagnosis

Secondary Outcomes (3)

All-cause mortality
From enrolment to 12 months after diagnosis
Cardiovascular Mortality
From enrolment to 12 months after diagnosis
Hospitalization for Heart Failure
From enrolment to 12 months after diagnosis

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Eligible participants would include adult patients (\>18 years) attending HF clinics in hospital or community settings or those hospitalized for the management of Acute Decompensated Heart failure (ADHF), who have been newly diagnosed HF with a left ventricular ejection fraction of \<50%, no more than 12 weeks prior. Patients would be excluded if they have had a previous diagnosis of heart failure, are on a palliative care pathway or are unable or unwilling to consent.

You may qualify if:

Age \>18 years
Newly diagnosed Heart Failure with a Left Ventricular Ejection Fraction \<50% (≤12 Weeks prior to enrolment).
Able and willing to consent.

You may not qualify if:

LVEF 50% or more at time of diagnosis
Palliative care
Unable or unwilling to give consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Mid and South Essex NHS Foundation Trustlead
Anglia Ruskin Universitycollaborator
British Society for Heart Failurecollaborator

Study Sites (2)

Mid and South Essex NHS Foundation Trust

Basildon, Essex, SS16 5NL, United Kingdom

RECRUITING

British Heart Foundation Glasgow Cardiovascular Research Centre, Glasgow

Glasgow, United Kingdom

NOT YET RECRUITING

Related Publications (5)

UK HFpEF Collaborative Group. Rationale and design of the United Kingdom Heart Failure with Preserved Ejection Fraction Registry. Heart. 2024 Feb 12;110(5):359-365. doi: 10.1136/heartjnl-2023-323049.
PMID: 37827557BACKGROUND
National Institute for Cardiovascular Outcomes Research (NICOR). https://www.nicor.org.uk/~documents/route%3A/download/2765. 2024 [cited 2025 Jan 30]. National Heart failure Audit (NHFA) 2024 Summary Report.
BACKGROUND
Nallamothu BK, Hayward RA, Bates ER. Beyond the randomized clinical trial: the role of effectiveness studies in evaluating cardiovascular therapies. Circulation. 2008 Sep 16;118(12):1294-303. doi: 10.1161/CIRCULATIONAHA.107.703579. No abstract available.
PMID: 18794402BACKGROUND
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW; ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May 3;145(18):e895-e1032. doi: 10.1161/CIR.0000000000001063. Epub 2022 Apr 1.
PMID: 35363499BACKGROUND
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-3726. doi: 10.1093/eurheartj/ehab368. No abstract available.
PMID: 34447992BACKGROUND

MeSH Terms

Conditions

Heart Failure

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular Diseases

Study Officials

Henry Oluwasefunmi Savage
Mid and South Essex NHS Foundation Trust
PRINCIPAL INVESTIGATOR

Central Study Contacts

Henry Oluwasefunmi Savage, MD FRCP

CONTACT

+44 01268524900 henry.savage@nhs.net

Sophie Harris

CONTACT

+44 0126852490 mse.quad-hf-study@nhs.net

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Target Duration: 60 Months
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

September 12, 2025

First Posted

September 15, 2025

Study Start

October 6, 2025

Primary Completion (Estimated)

November 1, 2030

Study Completion (Estimated)

November 1, 2031

Last Updated

December 16, 2025

Record last verified: 2025-09

Data Sharing

IPD Sharing: Will not share

Locations

GB(2)

QUAD-HF - Prospective Registry of Patients With Incident Heart Failure and Left Ventricular Ejection Fraction <50%

Brief Summary

Trial Health

Trial Health Score

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (3)

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (2)

Related Publications (5)

Related Links

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

Data Sharing

Locations

Brief Summary

Trial Health

Trial Health Score

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (3)

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (2)

Related Publications (5)

Related Links

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

Data Sharing

Locations